Safety and Immunogenicity of DNA Prime and Modified Vaccinia Ankara Virus-HIV Subtype C Vaccine Boost in Healthy Adults

A randomized, double-blind, placebo-controlled phase I trial was conducted in 32 HIV-uninfected healthy volunteers to assess the safety and immunogenicity of 3 doses of DNA vaccine (Advax) plus 1 dose of recombinant modified vaccinia virus Ankara (MVA) (TBC-M4) or 3 doses of TBC-M4 alone (groups A a...

Full description

Saved in:
Bibliographic Details
Main Authors: Hayes, Peter, Gilmour, Jill, von Lieven, Andrea, Gill, Dilbinder, Clark, Lorna, Kopycinski, Jakub, Cheeseman, Hannah, Chung, Amy, Alter, Galit, Dally, Len, Zachariah, Devika, Lombardo, Angela, Ackland, James, Sayeed, Eddy, Jackson, Akil, Boffito, Marta, Gazzard, Brian, Fast, Patricia E., Cox, Josephine H., Laufer, Dagna
Format: Artigo
Language:Inglês
Published: American Society for Microbiology 2013
Subjects:
Vaccines
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3592345/
https://ncbi.nlm.nih.gov/pubmed/23345581
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/CVI.00637-12
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items